

Otezla Prior Authorization (PA) Checklist



Otezla (apremilast) offers this checklist to help organize PA information and documentation. Detailed clinical documentation may expedite PA approval for patients to access Otezla.

Was Otezla prescribed by, or in consultation with, a dermatologist or rheumatologist? Yes No

Diagnosis Code¹

- | | | |
|--|---|---|
| <input type="checkbox"/> L40.50 (Arthropathic psoriasis, unspecified) | <input type="checkbox"/> L40.53 (Psoriatic spondylitis) | <input type="checkbox"/> L40.8 (Other psoriasis) |
| <input type="checkbox"/> L40.51 (Distal interphalangeal psoriatic arthropathy) | <input type="checkbox"/> L40.59 (Other psoriatic arthropathy) | <input type="checkbox"/> L40.9 (Psoriasis, unspecified) |
| <input type="checkbox"/> L40.52 (Psoriatic arthritis mutilans) | <input type="checkbox"/> L40.0 (Psoriasis vulgaris) | <input type="checkbox"/> M35.2 (Behçet's disease) |

Body Surface Area (BSA) Assessment – for Plaque Psoriasis²

BSA involvement: _____ %

BSA involvement of: Hands Feet Nails Scalp Groin Other _____

Treatment History

Prescription Topicals³

- Clobetasol
- Triamcinolone
- Fluocinolone
- Betamethasone
- Desoximetasone
- Halobetasol
- Calcipotriene
- Tacrolimus
- Fluocinolone acetonide
- Calcipotriene and betamethasone dipropionate

Oral Systemics^{3,4}

- Acitretin
- Cyclosporine
- Methotrexate
- Leflunomide
- Sulfasalazine
- Colchicine
- NSAIDs

Other Therapies to Note³

- Phototherapy
- Biologic therapies

Reasons for Discontinuation

Inadequate response

Please specify with additional information

Intolerance

Please specify with additional information

Does the patient have a contraindication to any treatments? If yes, please specify and provide any additional information. Some plans might require supporting documentation.

Questions? Call 1-844-4Otezla or visit OtezlaPro.com for additional resources

INDICATIONS

Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease.

IMPORTANT SAFETY INFORMATION

Contraindications

- Otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

Please see additional Important Safety Information on reverse and Full Prescribing Information [here](#).

This resource is informational only and not intended to be directive or a guarantee of coverage.

Important Safety Information

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions

- **Hypersensitivity:** Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapy
- **Diarrhea, Nausea, and Vomiting:** Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
- **Depression:** Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
 - **Plaque Psoriasis:** Treatment with Otezla is associated with an increase in depression. During clinical trials in patients with moderate to severe plaque psoriasis, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide
 - **Psoriatic Arthritis:** Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo-treated patients. Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo-treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla
 - **Behçet's Disease:** Treatment with Otezla is associated with an increase in depression. During the clinical trial, 1% (1/104) reported depression or depressed mood compared to 1% (1/103) treated with placebo. No instances of suicidal ideation or behavior were reported in patients treated with Otezla or treated with placebo
- **Weight Decrease:** Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
 - **Plaque Psoriasis:** Body weight loss of 5-10% occurred in 12% (96/784) of patients with moderate to severe plaque psoriasis treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of $\geq 10\%$ occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo
 - **Psoriatic Arthritis:** Body weight loss of 5-10% was reported in 10% (49/497) of patients taking Otezla and in 3.3% (16/495) of patients taking placebo
 - **Behçet's Disease:** Body weight loss of $>5\%$ was reported in 4.9% (5/103) of patients taking Otezla and in 3.9% (4/102) of patients taking placebo
- **Drug Interactions:** Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

Adverse Reactions

- **Plaque Psoriasis:** The most common adverse reactions ($\geq 5\%$) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache. Overall, the safety profile of Otezla in patients with mild to moderate plaque psoriasis was consistent with the safety profile previously established in adult patients with moderate to severe plaque psoriasis
- **Psoriatic Arthritis:** The most common adverse reactions ($\geq 5\%$) are diarrhea, nausea, and headache
- **Behçet's Disease:** The most common adverse reactions ($\geq 10\%$) are diarrhea, nausea, headache, and upper respiratory tract infection

Use in Specific Populations

- Otezla has not been studied in pregnant women. Advise pregnant women of the potential risk of fetal loss

Please click here for the full Prescribing Information for Otezla.

References: 1. Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. <https://www.cms.gov/files/zip/2021-code-tables-tabular-and-index-updated-12162020.zip>. Accessed February 23, 2021. 2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019;80:1029-1072. 3. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol.* 2021;84:432-470. 4. Menter A, Gelfand JM, Connor C, et al. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol.* 2020;82:1445-1486.

This resource is informational only and not intended to be directive or a guarantee of coverage.